Kit for detection of acute T-lymphocytic leukemia naive T cells and application and method thereof

Abstract

The invention discloses a kit for detection of acute T-lymphocytic leukemia naive T cells, application and a method thereof, and belongs to the field of biological medicine. The adopted technical scheme is as below: the kit for the detection of acute T-lymphocytic leukemia naive T cells can be applied to a flow cytometry, and includes monoclonal antibodies aiming at the following materials: TDT, ccd3, CD34, CD5, CD7, mCD3 and CD45. The antibodies respectively have fluorescent labels. The invention also provides the application of the above kit to the preparation of products for diagnosis of acute T-lymphocytic leukemia. The invention has the beneficial effects that: (1) the kit provided by the invention can quickly and accurately conduct analysis and quantification on trace LBTC antigen of all T-ALL patients; and (2) the gating method and multiple antigen markers integral evaluation provided by the kit has high specific degree and high sensitivity.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to a special kit for cell phenotype confirmation, in particular to a kit, application and method for analyzing the phenotype of leukemia naive T cells (leukemic blast T cells, LBTC) in acute T lymphocytic leukemia. Background technique [0002] T-lineage acute lymphoblastic leukemia (T-ALL) accounts for 15% and 25% of childhood acute lymphoblastic leukemia (ALL) and adult ALL, respectively, with large heterogeneity. With the optimization of treatment regimens, the induction remission rate and long-term survival rate of children's ALL have been significantly improved, but the prognosis of T-ALL is still poor; the overall 5-year event-free survival of adult ALL is only about 30%, while that of T-ALL is only about 30%. Long-term survival is worse in ALL. Due to the limited detection level of minimal residues at present, recurrence has become the main reason for treatment failure of T-ALL patie...

AI Technical Summary

Problems solved by technology

Early naive T cells in the thymus expressed CD34 and / or TdT, and the main antigens at that time were TdT and CD7. Therefore, it was considered that when the proportion of TdT+CD7+ naive T cells in the bone marrow or peripheral blood increased, it was positive for minimal residual disease, but for After T-ALL treatment, the proportion of CD34+TdT+cCD3+ T cells in the bone marrow increased, whether it is LBTC, whether it means the increase of leukemia cells or non-specific binding is not clear

Images